The physiology of MASLD: molecular pathways between liver and adipose tissues
Clinical Science · 24.09.2025 · 139 (18) · 1015-1046
DOI: 10.1042/cs20257571 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Science, online erschienen am 22.09.2025. Verfasst von Wang-Hsin Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Drug & Disease Discovery D3 Research Center, Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexingt…. Hauptthemen laut MEDLINE: Adipose Tissue, Liver, Fatty Liver. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 319 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NIDA NIH HHS.
Abstract (Originalsprache)
The global prevalence of obesity has exerted a profound influence on human health. It has contributed to numerous obesity-related comorbidities, including metabolic dysfunction-associated steatotic liver disease (MASLD) and insulin-resistant diabetes. MASLD is diagnosed when there is substantial fat accumulation concomitant with five additional diagnostic criteria. If untreated, MASLD may progress to liver fibrosis and cirrhosis, conditions that can be life-threatening in the final stages. Nonetheless, the development and progression of MASLD are complex, and its underlying mechanisms remain incompletely elucidated. Typically, during fasting, adipose tissue releases fatty acids, which the liver subsequently uptakes for gluconeogenesis. However, this process, along with many others, is impaired in the liver and adipose tissue of individuals with MASLD. This review provides comprehensive details on the mechanisms underlying adiposity and insulin resistance associated with MASLD. We discuss the canonical pathways that promote lipogenesis and insulin sensitivity in the liver and adipose tissues, including bile acids, bilirubin, fatty acids, inflammation, de novo lipogenesis, oxidative stress, peroxisome proliferator-activated receptors (PPARs), fibroblast growth factor 21 (FGF21), glucagon-like peptide 1 (GLP1), and metabolism of fructose. The scope of the review is expanded to encompass biological responses to fasting and feeding, as well as their effects on fat accumulation and insulin sensitivity in these tissues. Additionally, the review elaborates on critical molecular mechanisms regulating MASLD progression, including hepatic insulin clearance, insulin degradation, bilirubin metabolism, nerve innervation, and the roles of cytokines and adipokines. Overall, this review examines the mechanisms driving MASLD and explores potential novel therapeutic strategies for its management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Drug & Disease Discovery D3 Research Center, Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, U.S.A.
- Barnstable Brown Diabetes Center, University of Kentucky College of Medicine, Lexington, KY, U.S.A.
- Markey Cancer Center, University of Kentucky, Lexington, KY, U.S.A.
ORCID-Profile: Wang-Hsin Lee, Zachary A Kipp, Evelyn A Bates, Sally N Pauss, Genesee J Martinez, Terry D Hinds
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- NIDA NIH HHS
Zitieren
APA
Lee, W. H., Kipp, Z. A., Bates, E. A., Pauss, S. N., Martinez, G. J., & Hinds, T. D. (2025). The physiology of MASLD: molecular pathways between liver and adipose tissues. Clinical Science, 139(18), 1015-1046. https://doi.org/10.1042/cs20257571
Vancouver
Lee WH, Kipp ZA, Bates EA, Pauss SN, Martinez GJ, Hinds TD. The physiology of MASLD: molecular pathways between liver and adipose tissues. Clinical Science. 2025;139(18):1015-1046. doi:10.1042/cs20257571
BibTeX
@article{Lee2025,
author = {Lee, Wang-Hsin and Kipp, Zachary A and Bates, Evelyn A and Pauss, Sally N and Martinez, Genesee J and Hinds, Terry D},
title = {The physiology of MASLD: molecular pathways between liver and adipose tissues},
journal = {Clinical Science},
year = {2025},
volume = {139},
number = {18},
pages = {1015--1046},
doi = {10.1042/cs20257571}
}
EUVIMED